Found: 4
Select item for more details and to access through your institution.
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy.
- Published in:
- Science Translational Medicine, 2020, v. 12, n. 549, p. 1, doi. 10.1126/scitranslmed.aba2325
- By:
- Publication type:
- Article
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
- Published in:
- Science Translational Medicine, 2020, v. 12, n. 525, p. 1, doi. 10.1126/scitranslmed.aaw7888
- By:
- Publication type:
- Article
Interference in a Neutralizing Antibody Assay for Odronextamab, a CD20xCD3 Bispecific mAb, from Prior Rituximab Therapy and Possible Mitigation Strategy.
- Published in:
- AAPS Journal, 2022, v. 24, n. 4, p. 1, doi. 10.1208/s12248-022-00724-y
- By:
- Publication type:
- Article
VSIG4 interaction with heparan sulfates inhibits VSIG4–complement binding.
- Published in:
- Glycobiology, 2023, v. 33, n. 7, p. 591, doi. 10.1093/glycob/cwad050
- By:
- Publication type:
- Article